These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27211090)

  • 61. Personalized management of patients with very early hypovascular hepatocellular carcinoma.
    Cucchetti A; Vitale A
    Liver Int; 2018 Mar; 38(3):415-416. PubMed ID: 29469211
    [No Abstract]   [Full Text] [Related]  

  • 62. Visualization and segmentation of liver tumors using dynamic contrast MRI.
    Raj A; Juluru K
    Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():6985-9. PubMed ID: 19964723
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatocellular carcinoma: optimal staging impacts survival.
    Reeves HL; Aisen AM
    Gastroenterology; 2015 Jun; 148(7):1274-6. PubMed ID: 25921373
    [No Abstract]   [Full Text] [Related]  

  • 64. Hepatobiliary contrast agents in MR: Where we stand and future perspectives.
    Rimola J; Forner A
    Liver Int; 2021 May; 41(5):888-890. PubMed ID: 33861894
    [No Abstract]   [Full Text] [Related]  

  • 65. Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet.
    Forner A; Rimola J; Ayuso C
    J Hepatol; 2016 Sep; 65(3):648-9. PubMed ID: 27312943
    [No Abstract]   [Full Text] [Related]  

  • 66. Reply to: "Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet".
    Choi SH; Byun JH
    J Hepatol; 2016 Sep; 65(3):650-1. PubMed ID: 27349489
    [No Abstract]   [Full Text] [Related]  

  • 67. Improving Postsurgical Outcome in Patients with HCC by Using a Hepatobiliary Contrast Agent.
    Motosugi U
    Radiology; 2019 Dec; 293(3):605-606. PubMed ID: 31596183
    [No Abstract]   [Full Text] [Related]  

  • 68. Contrast enhanced ultrasound and magnetic resonance imaging for hepatoma diagnosis.
    Wiwanitkit V
    Med Ultrason; 2014 Mar; 16(1):80. PubMed ID: 24567932
    [No Abstract]   [Full Text] [Related]  

  • 69. Time to update radiological criteria for non-invasive diagnosis of hepatocellular carcinoma.
    Saini S; Pratt DS
    Hepatol Int; 2015 Jan; 9(1):1-2. PubMed ID: 25788371
    [No Abstract]   [Full Text] [Related]  

  • 70. The radiologist as interpreter and translator.
    Baron RL
    Radiology; 2014 Jul; 272(1):4-8. PubMed ID: 24956044
    [No Abstract]   [Full Text] [Related]  

  • 71. Hepatocellular Carcinoma Surveillance with Abbreviated MRI Strategies.
    Consul N
    Radiol Imaging Cancer; 2021 Jan; 3(1):e219002. PubMed ID: 33778767
    [No Abstract]   [Full Text] [Related]  

  • 72. Author's response.
    Gheonea IA; Sandulescu L; Saftoiu A
    Med Ultrason; 2014 Mar; 16(1):81-2. PubMed ID: 24707553
    [No Abstract]   [Full Text] [Related]  

  • 73. A highly sensitive x-ray imaging modality for hepatocellular carcinoma detection in vitro.
    Rand D; Walsh EG; Derdak Z; Wands JR; Rose-Petruck C
    Phys Med Biol; 2015 Jan; 60(2):769-84. PubMed ID: 25559398
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Using Contrast-enhanced US for Hepatocellular Carcinoma Assessment: Contrast-enhanced US LI-RADS version 2017 Classification Is Diagnostically Accurate.
    Sidhu PS
    Radiology; 2020 Feb; 294(2):308-309. PubMed ID: 31770078
    [No Abstract]   [Full Text] [Related]  

  • 75. Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement Criteria.
    Piscaglia F; Kudo M; Han KH; Sirlin C
    Ultraschall Med; 2017 Jan; 38(1):9-11. PubMed ID: 28249327
    [No Abstract]   [Full Text] [Related]  

  • 76. Letter to the editor.
    Lyske J; Sathyanarayana R
    Abdom Radiol (NY); 2017 Nov; 42(11):2781-2782. PubMed ID: 28478491
    [No Abstract]   [Full Text] [Related]  

  • 77. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Singal AG; Llovet JM; Yarchoan M; Mehta N; Heimbach JK; Dawson LA; Jou JH; Kulik LM; Agopian VG; Marrero JA; Mendiratta-Lala M; Brown DB; Rilling WS; Goyal L; Wei AC; Taddei TH
    Hepatology; 2023 Dec; 78(6):1922-1965. PubMed ID: 37199193
    [No Abstract]   [Full Text] [Related]  

  • 78. Comment on "State of the art in magnetic resonance imaging of hepatocellular carcinoma": the role of DWI.
    Granata V; Fusco R; Filice S; Incollingo P; Belli A; Izzo F; Petrillo A
    Radiol Oncol; 2019 Jul; 53(3):369-370. PubMed ID: 31318697
    [No Abstract]   [Full Text] [Related]  

  • 79. The role of imaging techniques in clinical decision making for the management of hepatocellular carcinoma.
    Lo GH
    Hepatology; 2012 Aug; 56(2):786. PubMed ID: 22290598
    [No Abstract]   [Full Text] [Related]  

  • 80. Postoperative Recurrence of Hepatocellular Carcinoma: The Importance of Distinguishing between Intrahepatic Metastasis and Multicentric Occurrence-Response.
    Kim S; Shin J; Kim DY; Choi GH; Kim MJ; Choi JY
    Clin Cancer Res; 2019 Sep; 25(17):5427. PubMed ID: 31481487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.